Technical Data
I7661-16B9
Insulin-Like Growth Factor Binding Protein 1, Recombinant, Human (IGFBP1)
25ug
Growth Factors, Cytokines Storage: -20°CShipping: RT
The superfamily of insulin­like growth factor (IGF) binding proteins include the six high­affinity IGF binding proteins (IGFBP) and at least four additional low­affinity binding proteins referred to as IGFBP related proteins (IGFBP­rP). All IGFBP superfamily members are cysteine­rich proteins with conserved cysteine residues, which are clustered in the amino­ and carboxy­terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post­transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.
Human IGFBP­1 cDNA encodes a 259 amino acid (aa) residue precursor protein with a putative 25aa residue signal peptide that is processed to generate the 234aa residue mature protein. IGFBP­1 contains an integrin receptor recognition sequence
(RGD sequence) but lacks potential N­linked glycosylation sites. IGFBP­1 is expressed in liver, decidua, kidneys and is the most abundant IGFBP in amniotic fluid. Serum levels of IGFBP­1 are lowest after meals. Hepatocyte production of IGFBP­1 is regulated at the transcriptional level due to the affects of insulin and corticosteriods. IGFBP­1 binds equally well to IGF­I and IGF­II, with phosphorylated forms of IGFBP­1 exhibiting higher binding affinities.

Source:
Recombinant corresponding to aa26-259 from human Insulin-Like Growth Factor Binding Protein 1 expressed in NSO cells (P08833).

N­terminal Sequence: Ala26

SDS-PAGE: 32kD, reducing conditions

Biological Activity:
Measured by its ability to inhibit the biological activity of IGF-I or IGF­II on MCF­7 human breast adenocarcinoma cells. The ED50 for this effect is typically 1-4ug/ml in the presence of 6ng/ml recombinant human IGF­I.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with PBS. Aliquot and store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
25kD
 Source: Recombinant, Human (NSO cells)
Purity: ~97% by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin: 1.0EU/ug (LAL)
Concentration: ~0.1mg/ml (after reconstitution)
Form: Supplied as a lyophilized powder from PBS, pH 7.4.
Reconstitute in sterile PBS, to a concentration of 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3. 2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619. 3. Karey K.P. et al Cancer Reserch 48:4083 (1988).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.